Last updated on May 2018

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102


Brief description of study

A Phase 1/2 Open-Label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous AEB1102

Detailed Study Description

This study is designed to evaluate the safety and tolerability of IV administration of AEB1102 for the treatment of pediatric and adult patients with Arginase I deficiency and hyperargininemia. This study will be conducted in 2 parts: Part 1 (Single Ascending Dose Escalation) and Part 2 (Repeated Dosing). Each part will be preceded by a baseline assessment of arginine levels. All patients who participate in Part 1 may continue AEB1102 dosing in Part 2 if they qualify for continued dosing.

Clinical Study Identifier: TX152713

Contact Investigators or Research Sites near you

Start Over

Aeglea Study Site

Study Coordinator
New York, NY United States
  Connect »

Aeglea Study Site

Study Coordinator
Stanford, CA United States
  Connect »

Aeglea Study Site

Study Coordinator
Salt Lake City, UT United States
  Connect »

Aeglea Study Site

Study Coordinator
Toronto, Ontario Canada
  Connect »

Aeglea Study Site

Study Coordinator
Dallas, TX United States
  Connect »

Aeglea Study Site

Study Coordinator
Pittsburgh, PA United States
  Connect »

Aeglea Study Site

Study Coordinator
Seattle, WA United States
  Connect »

Aeglea Study Site

Study Coordinator
Gainesville, FL United States
  Connect »